Respondents stated that the cost and cost effectiveness of routine G6PD testing was an important barrier to its introduction, as was the need for additional training of healthcare staff.“The price of [the] test should be subsidized...[so that] Cambodia can buy [the test]....The G6PD test must have price cheaper than price of malaria treatment.” Policy maker. This evidence concerns the gene G6PD and malaria.